The U.S. government claims US Bioservices encouraged patients to refill prescriptions for Exjade in exchange for referrals and higher rebates from the Swiss Pharmaceutical company. The lawsuit claims U.S. Bioservices had its nurses call patients with one-sided advice emphasizing the dangers of not treating increased iron levels and downplaying the risks of the drug.
The lawsuit further contends US Bioservices illegally billed government payers for prescriptions that stemmed from the kickback scheme.
US Bioservices competed for referrals from Novartis with two other specialty pharmacies; BioScrip and Accredo Health Group, which both recently settled kickback allegations by paying a total of $75 million.
US Bioservices’ $13.4 million settlement must still be approved by the court.
More articles on supply chain:
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Walmart follows Amazon, applies for aerial warehouse patent
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
